大环内酯类药物治疗慢性鼻-鼻窦炎的进展

申珅; 王成硕

doi:10.13201/j.issn.1001-1781.2018.09.019

大环内酯类药物治疗慢性鼻-鼻窦炎的进展

申珅^1,2,
王成硕^1,2, ,

- 1. 首都医科大学附属北京同仁医院耳鼻咽喉头颈外科(北京, 100730);
- 2. 鼻病研究北京市重点实验室北京市耳鼻咽喉科研究所
基金项目:
首都卫生发展科研专项 (No:首发2016-1-2052)

详细信息

通讯作者: 王成硕, E-mail:wangcs830@126.com

中图分类号: R765

收稿日期: 2018-02-03

A progress of macrolides therapy for chronic rhinosinusitis

More Information

Corresponding author: , E-mail: wangcs830@126.com

Received Date: 03 February 2018

摘要

- 大环内酯类药物 /
- 慢性鼻-鼻窦炎 /
- 弥漫性泛细支气管炎 /
- 慢性阻塞性肺疾病 /
- 支气管哮喘 /
- 肺囊性纤维化
Abstract: Macrolides are a type of antibiotics with macrocyclic lactone ring, which have been commonly used in the treatment of diffuse panbronchiolitis, chronic obstructive pulmonary disease, bronchial asthma, cystic fibrosis and other diseases.Macrolides not only have effect on antibacterial, but also effect on anti-inflammatory and immunoregulation.Chronic rhinosinusitis (CRS) is a common disease entity of infectious and inflammatory diseases that involved in nasal cavity and nasal sinuses, with various clinical phenotypes.With the high prevalence of CRS, it seriously affects the quality of patients' life.In recent years, a large number of studies have shown that long-term low-dose macrolides are effective in parts of patients with CRS.Although the mechanism of macrolides for CRS has not yet been clarified.According to recent studies, it might be related with anti-inflammatory or immunoregulation of macrolides and the different phenotypes of CRS.The safety and mechanism of long-term macrolides are needed further clarification.
- macrolides /
- chronic rhinosinusitis /
- diffuse panbronchiolitis /
- chronic obstructive pulmonary disease /
- bronchial asthma /
- pulmonary cystic fibrosis

HTML全文

参考文献(67)

[1]	王成硕, 张罗.慢性鼻窦炎的治疗策略[J].临床耳鼻咽喉头颈外科杂志, 2016, 30 (14):1175-1178.
[2]	AMINOV R.History of antimicrobial drug discovery:major classes and health impact[J].Biochem Pharmacol, 2017, 133:4-19.
[3]	BEARDEN D T, RODVOLD K A.Penetration of macrolides into pulmonary sites of infection[J].Infect Med, 1999, 16:480-484.
[4]	BROCKMANN H, HENKEL W.Pikromycin, ein neues Antibiotikum aus Actinomyceten[J].Naturwissenschaften, 1950, 37:138-139.
[5]	BROCKMANN H, HENKEL W.Pikromycin, ein bitter schmeckendes Antibioticum aus Actinomyceten (Antibiotica aus Actinomyceten, Ⅵ.Mitteil)[J]?Chem Ber, 1951, 84:284-288.
[6]	KITTENDORF J D, SHERMAN D H.The methymycin/pikromycin pathway:a model for metabolic diversity in natural product biosynthesis[J].Bioorg Med Chem, 2009, 17:2137-2146.
[7]	MCGUIRE J M, BUNCH R L, ANDERSON R C, et al.Ilotycin, a new antibiotic[J].Schweiz Med Wochenschr, 1952, 82:1064-1065.
[8]	SHINKAI M, HENKE M O, RUBIN B K.Macrolide antibiotics as immunomodulatory medications:Proposed mechanisms of action[J].Pharmacol Ther, 2008, 117:393-405.
[9]	AZUMA A, KUDOH S.Diffuse panbronchiolitis in East Asia[J].Respirology, 2006, 11:249-261.
[10]	KUDOH S, AZUMA A, YAMAMOTO M, et al.Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin[J].Am J Respir Crit Care Med, 1998, 157:1829-1832.
[11]	BISGAARD H, HERMANSEN M N, BUCHVALDF, et al.Childhood asthma after bacterial colonization of the airway in neonates[J].N Engl J Med, 2007, 357:1487-1495.
[12]	MARTIN R J, KRAFT M, CHU H W, et al.A link between chronic asthma and chronic infection[J].JAllergy Clin Immunol, 2001, 107:595-601.
[13]	MORIKAWA K, OSEKO F, MORIKAWA S, et al.Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro[J].Antimicrob Agents Chemother, 1994, 38:2643-2647.
[14]	SPAHN J D, FOST D A, COVAR R, et al.Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma:results of a pilot study[J].Ann Allergy Asthma Immunol, 2001, 87:501-505.
[15]	SIMPSON J L, POWELL H, BOYLE M J, et al.Clarithromycin targets neutrophilic airway inflammation in refractory asthma[J].Am J Respir Crit Care Med, 2008, 177:148-155.
[16]	VESTBO J, EDWARDS L D, SCANLON P D, et al.Changes in forced expiratory volume in 1second over time in COPD[J].N Engl J Med, 2011, 365:1184-1192.
[17]	SUZUKI T, YANAI M, YAMAYA M, et al.Erythromycin and common cold in COPD[J].Chest, 2001, 120:730-733.
[18]	TSAI W C, STANDIFORD T J.Immunomodulatory effects of macrolides in the lung:lessons from in-vitro and in-vivo models[J].Curr Pharm Des, 2004, 10:3081-3093.
[19]	LABRO M T.Cellular and molecular effects of macrolides on leukocyte function[J].Curr Pharm Des, 2004, 10:3067-3080.
[20]	HODGE S, HODGE G, JERSMANN H, et al.Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med, 2008, 178:139-148.
[21]	SCHMIDT-GLINTZER H.Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophagesin chronic obstructive pulmonary disease subjects[J].Respirology, 2012, 17:802-807.
[22]	SETHI S, MALONEY J, GROVE L, et al.Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med, 2006, 173:991-998.
[23]	EQUI A, BALFOURLYNN I M, BUSH A, et al.Long term azithromycin in children with cystic fibrosis:a randomised, placebo-controlled crossover trial[J].Lancet, 2002, 360:978-984.
[24]	SAIMAN L, ANSTEAD M, MAYERHAMBLETTN, et al.Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa:a randomized controlled trial[J].JAMA, 2010, 303:1707-1715.
[25]	KUDOH S, UETAKE T, HAGIWARA K, et al.Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis[J].Nihon Kyōbu Shikkan Gakkai Zasshi, 1987, 25:632-642.
[26]	KIKUCHI S, SUZAKI H, AOKI A, et al.Clinical effect of long-term low-dose erythromycin therapy for chronic sinusitis[J].Practotol, 1991, 84:41-47.
[27]	KIKUCHI S, YAMASOBA T, SUZAKI H, et al.Long-term low-dose erythromycin therapy for chronic sinusitis[J].Practotol, 1992, 85:41-47.
[28]	CERVIN A, WALLWORK B.Macrolide therapy of chronic rhinosinusitis[J].Rhinology, 2007, 45:259.
[29]	VIDELER W J, BADIA L, HARVEY R J, et al.Lack of efficacy of long-term, low-dose azithromycin in chronic rhinosinusitis:a randomized controlled trial[J].Allergy, 2011, 66:1457-1468.
[30]	ZENG M, LONG X B, CUI Y H, et al.Comparison of efficacy of mometasone furoate versus clarithromycin in the treatment of chronic rhinosinusitis without nasal polyps in Chinese adults[J].Am J Rhinol Allergy, 2011, 25:e203-e207.
[31]	WALLWORK B, COMAN W, MACKAY-SIM A, et al.A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis[J].Laryngoscope, 2006, 116:189-193.
[32]	PYNNONEN M A, VENKATRAMAN G, DAVIS GE.Macrolide therapy for chronic rhinosinusitis:a meta-analysis[J].Otolaryngol Head Neck Surg, 2013, 148:366-373.
[33]	LUO Q, CHEN F, LIU W, et al.Evaluation of longterm clarithromycin treatment in adult Chinese Patients with chronic rhinosinusitis without nasal polyps[J].ORL, 2011, 73:206-211.
[34]	FAN Y, CHEN S, QU X, et al.A lower prevalence of asthma among patients with chronic rhinosinusitis in southern China[J].J Allergy Clin Immunol, 2011, 127:1-5.
[35]	CAO P P, LI H B, WANG B F, et al.Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese[J].J Allergy Clin Immunol, 2009, 124:1-2.
[36]	李华斌, 冯韶燕, 程岚.嗜酸粒细胞性慢性鼻窦炎的临床特点和治疗策略[J].临床耳鼻咽喉头颈外科杂志, 2016, 30 (3):177-179.
[37]	王成硕, 娄鸿飞, 娄玮, 等.短期布地奈德混悬液经鼻雾化治疗慢性鼻窦炎伴鼻息肉的疗效和安全性研究[J].临床耳鼻咽喉头颈外科杂志, 2012, 26 (8):347-350.
[38]	PERIC A, BALETIC N, MILOJEVIC M, et al.Effects of preoperative clarithromycin administration in patients with nasal polyposis[J].West Indian Med J, 2014, 63:721-727.
[39]	LOU H, MENG Y, PIAO Y, et al.Cellular phenotyping of chronic rhinosinusitis with nasal polyps[J].Rhinology, 2016, 54:150-159.
[40]	HARUNA S, SHIMADA C, OZAWA M, et al.Astudy of poor responders for long-term, low-dose macrolide administration for chronic sinusitis[J].Rhinology, 2009, 47:66-71.
[41]	ANASTASIA V, ANDREY L.Efficacy of long-term low-dose macrolide therapy in preventing early recurrence of nasal polyps after endoscopic sinus surgery[J].Int Forum Allergy Rhinol, 2014, 24:533-541.
[42]	ZHANG N, VAN ZELE T, PEREZ-NOVO C, et al.Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease[J].J Allergy Clin Immunol, 2008, 122:961-968.
[43]	YAMADA T, FUJIEDA S, MORI S, et al.Macrolide treatment decreased the size of nasal polyps and IL-8levels in nasal lavage[J].Am J Rhinol, 2000, 14:143-148.
[44]	OLIVEIRA I S D, CASSALI G D, REIS D C D, et al.Evaluation of the improvement of quality of life with Azithromycin in the treatment of eosinophilic nasal polyposis[J].Braz J Otorhinolaryngol, 2016, 82:198-202.
[45]	ICHIMURA K, SHIMAZAKI Y, ISHIBASHI T, et al.Effect of new macrolide roxithromycin upon nasal polyps associated with chronic sinusitis[J].Auris Nasus Larynx, 1996, 23:48-56.
[46]	MITSUYA Y, KAWAI S, KOBAYASHI H.Influence of macrolides on guanosine diphospho-D-mannose dehydrogenase activity in Pseudomonas biofilm[J].JInfect Chemother, 2000, 6:45-50.
[47]	WOZNIAK D J, KEYSER R.Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa[J].Chest, 2004, 125:62S-69S.
[48]	SPECTOR S L, KATZ F H, FARR R S.Troleandomycin:Effectiveness in steroid-dependent asthma and bronchitis[J].J Allergy Clin Immunol, 1974, 54:367-379.
[49]	BACHERT C, WAGENMANN M, RUDACK C, et al.The role of cytokines in infectious sinusitis and nasal polyposis[J].Allergy, 1998, 53:2-13.
[50]	DEMOLY P, CRAMPETTE L, MONDAIN M, et al.Myeloperoxidase and interleukin-8levels in chronic sinusitis[J].Clin Exp Allergy, 1997, 27:672-675.
[51]	MACLEOD C M, HAMID Q A, CAMERON L, et al.Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa[J].Adv Ther, 2001, 18:75-82.
[52]	NONAKA M, PAWANKAR R, SAJI F, et al.Effect of roxithromycin on IL-8synthesis and proliferation of nasal polyp fibroblasts[J].Acta Otolaryngol, 1998, 118:71-75.
[53]	PERIC A, VOJVODIC D, BALETIC N, et al.Influence of allergy on the immunomodulatory and clinical effects of long-term low-dose macrolide treatment of nasal polyposis[J].Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2010, 154:327-333.
[54]	MIYANOHARA T, USHIKAI M, MATSUNE S, et al.Effects of clarithromycin on cultured human nasal epithelial cells and fibroblasts[J].Laryngoscope, 2000, 110:126-131.
[55]	DESAKI M, TAKIZAWA H, OHTOSHI T, et al.Erythromycin suppresses nuclear factor-kappaB and activator protein-1activation in human bronchial epithelial cells[J].Biochem Biophys Res Commun, 2000, 267:124-128.
[56]	SAKITO O, KADOTA J, KOHNO S, et al.Interleukin 1beta, tumor necrosis factor alpha, and interleukin 8in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis:apotential mechanism of macrolide therapy[J].Respiration, 1996, 63:42-48.
[57]	AOSHIBA K, NAGAI A, KONNO K.Erythromycin shortens neutrophil survival by accelerating apoptosis[J].Antimicrob Agents Chemother, 1995, 39:872-877.
[58]	TAMAOKI J, TAKEYAMA K, YAMAWAKI I, et al.Lipopolysaccharide-induced goblet cell hypersecretion in the guinea pig trachea:inhibition by macrolides[J].Am J Physiol, 1997, 272:15-19.
[59]	BORSZCZ P D, BEFUS D, MOQBEL R, et al.Effects of clarithromycin on inflammatory cell mediator release and survival[J].Chemotherapy, 2005, 51:206-210.
[60]	ENOMOTO F, ANDOU I, NAGAOKA I, et al.Effect of new macrolides on the expression of adhesion molecules on neutrophils in chronic sinusitis[J].Auris Nasus Larynx, 2002, 29:267-269.
[61]	SHIMIZU T, SUZAKI H.Past, present and future of macrolide therapy for chronic rhinosinusitis in Japan[J].Auris Nasus Larynx, 2016, 43:131-136.
[62]	CERVIN A, KALM O, SANDKULL P, et al.Oneyear low-dose erythromycin treatment of persistent chronic sinusitis after sinus surgery:clinical outcome and effects on mucociliary parameters and nasal nitric oxide[J].Otolaryngol Head Neck Surg, 2002, 126:481-489.
[63]	SHINKAI M, RUBIN B K.Macrolides and airway inflammation in children[J].Paediatr Respir Rev, 2005, 6:227-235.
[64]	RAY W A, MURRAY K T, HALL K, et al.Azithromycin and the risk of cardiovascular death[J].New Engl J Med, 2012, 366:1881-1890.
[65]	MOSHOLDER A D, MATHEW J, ALEXANDER JJ, et al.Cardiovascular risks with azithromycin and other antibacterial drugs[J].New Engl J Med, 2013, 368:1665-1668.
[66]	PERITI P, MAZZEI T, MINI E, et al.Adverse effects of macrolide antibacterials[J].Drug Saf, 1993, 9:346-364.
[67]	ALBERT R K, CONNETT J, BAILEY W C, et al.Azithromycin for prevention of exacerbations of COPD[J].N Engl J Med, 2011, 365:689-698.